About OraSure Technologies
OraSure Technologies is a publicly listed company based in Bethlehem (United States) founded in 1987. Point-of-care diagnostic devices for oral fluid specimens are provided. It operates on a Direct-to-Consumer (D2C), Reseller / Distribution, and HealthTech model. The company has 501 employees. OraSure Technologies has completed 6 acquisitions, including CoreBiome, DNA Genotek and Diversigen. Its chief executive, as recorded, is Douglas A. Michels. Its website orasure.com draws about 12 thousand monthly visits. OraSure Technologies offers products and services including Rapid Diagnostic Tests and Sample Collection Devices. Its focus areas include Medical Devices and Diagnostic Equipment. Its legal entity is OraSure Technologies, Inc. Its competitors include Quantalife, Senzo and Hememics Biotechnologies; 3 of its 3 listed competitors have raised funding.
Company details
OraSure Technologies, Inc. is involved in the development, manufacture, and distribution of rapid diagnostic tests and sample collection solutions. The company operates within the healthcare sector, focusing on improving access, quality, and value of medical services. Products are distributed globally to clinical laboratories, hospitals, clinics, public health organizations, and direct to consumers. Subsidiaries like DNA Genotek and Sherlock Biosciences contribute to innovative solutions for detecting critical medical conditions such as HIV, HCV, and syphilis.
- Headquarters Bethlehem, United States
- Employees 501
- Stage Public
- SectorsHealthcare
- Website orasure.com
- Social LinkedIn Facebook Instagram
- Legal Name Orasure Technologies, Inc.
- Annual Revenue$115.02 M (USD)-38.1as on Dec 31, 2025
- Net Profit-$68.73 M (USD)-252.47as on Dec 31, 2025
- EBITDA-$57.93 M (USD)-495.52as on Dec 31, 2025
- InvestorsGates Foundation
& 2 more
- Employee Count501
- Investments & AcquisitionsCoreBiome
& 5 more
Products & Services of OraSure Technologies
OraSure Technologies offers a comprehensive portfolio of products and services, including Rapid Diagnostic Tests and Sample Collection Devices.
Rapid tests for detecting critical medical conditions are provided.
Devices for sample collection and stabilization are offered globally.
Funding Insights of OraSure Technologies
- Total Rounds 3
- First Round $145,915
(Jul 2012)
- Investors Count 3
All 3 funding rounds of OraSure Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | Grant | – | – | ||
| Jun 2017 | Grant | – | – | ||
| Jul 2012 | $145,915 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in OraSure Technologies
OraSure Technologies has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Gates Foundation, HHS and Public Health Emergency.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| phe.gov | ||||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for OraSure Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OraSure Technologies
99 people are tracked at OraSure Technologies (40 in leadership, 6 in board & advisors, 53 in team); the tracked headcount is 501.
| Name | Role | Group |
|---|---|---|
Douglas A. Michels | CEO & President | Leadership |
Rafal Iwasiow | VP, Science, Innovation & Technology | Leadership |
Katie Birkas | Director Clinical Operations | Leadership |
Carrie Eglinton Manner | President & CEO | Leadership |
Janice Merrill | Associate Director, Supply Chain | Leadership |
Wendy Kivens | Director, Regulatory Affairs | Leadership |
Guy Thompson II | Senior Director Of Operations | Leadership |
Joseph Oerson | Director Of Sales | Leadership |
Karen Davies | Senior Vice President, Research & Development | Leadership |
Shane Hebel | Senior Director, External Relations And HIV | Leadership |
Donnie Rizzo | Senior Director - New Products And Technologies | Leadership |
Keith Kardos | Head Of Research And New Diagnostics | Leadership |
Tiffany Miller | VP Regulatory Affairs | Leadership |
Fadi Findakly | Director Corporate Development | Leadership |
Scott Rabuka | Senior Director, Strategic Alliances | Leadership |
Ayesha Herrera | Director, Human Resources | Leadership |
Jerry Lydon | Senior Director Of Sales | Leadership |
Bill Dillman | Senior Director Of Supply Chain Management | Leadership |
Juan Carmona | Director Of Scientific Affairs And Professional Alliances | Leadership |
Mary Palmieri | Director Of Logistics | Leadership |
79 more people are available in the full profile.
Complete people profiles for OraSure Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of OraSure Technologies
OraSure Technologies is a publicly listed company on the NASDAQ with ticker symbol OSUR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Nov 1986
- Listed onNASDAQ: OSUR
- Listed entityOraSure Technologies, Inc.
- Exchange sectorHealth technology
- ISINUS68554V1089
- Share price$3.81 (-2.81% on the day) · 2026-10-13
- Market capitalisation$262.8M
- EPS (diluted, trailing year)$-0.69
- Volume (last session)559,677
Financials of OraSure Technologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $115.0M | -$68.7M | -$57.9M |
| 2024 | $185.8M | -$19.5M | -$9.7M |
| 2023 | $405.5M | $53.7M | $74.0M |
| 2022 | $387.5M | -$17.1M | $8.8M |
| 2021 | $233.7M | -$23.0M | $9,000 |
Detailed financial statements for OraSure Technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OraSure Technologies
OraSure Technologies has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include CoreBiome, DNA Genotek and Diversigen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Sherlock Biosciences is focused on molecular diagnostics development. | sherlock.bio | Watertown, United States | 2019 | Dec 2024 | •••• | |
Non-invasive urine test for HIV PrEP adherence monitoring is developed. | ursureinc.com | Boston, United States | 2015 | May 2020 | •••• | |
Metagenomic services for the health, agriculture, and oil and gas industries. | diversigen.com | Houston, United States | 2013 | Nov 2019 | $12M | |
Microbiome diversity is analyzed using big data methods. | corebiome.com | Minneapolis, United States | 2016 | Jan 2019 | •••• | |
Sampling and Intradermal Injection device | novosanis.com | Wijnegem, Belgium | 2013 | Jan 2019 | •••• | |
Biological sample collection kits for DNA and RNA are developed. | dnagenotek.com | Ottawa, Canada | 2010 | Jul 2011 | •••• |
Complete acquisition details for OraSure Technologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OraSure Technologies
10 dated milestones of OraSure Technologies across 38 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Founded OraSure Technologies is founded.
- Acquisition Acquires DNA Genotek.
- Funding First funding round of $146K.
- Acquisition Acquires Novosanis.
- Acquisition Acquires CoreBiome.
- Acquisition Acquires Diversigen.
- Acquisition Acquires UrSure.
- Funding Latest funding round, Grant,.
- Acquisition Acquires Sherlock Biosciences.
Competitors of OraSure Technologies
OraSure Technologies has 3 listed competitors in our database, 3 of them funded. They include Quantalife, Senzo and Hememics Biotechnologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quantalife.com | 2008 | Pleasanton, United States | $28.71M | Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. | ||
| senzo.com | 2013 | San Francisco, United States | $9.6M | 13 | Point-of-care diagnostic devices for infectious diseases are developed. | |
| hememics.com | 2009 | Gaithersburg, United States | $4.6M | 13 | Biopreservation platform for mammalian cells and biologics is developed. |
Detailed competitors of OraSure Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OraSure Technologies
The website of OraSure Technologies (orasure.com) receives about 11.7K visits a month.
- Monthly visits11.7K
▲ 5.8% vs previous month
Websites whose visitors overlap most with OraSure Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| trinitybiotech.com | 100% | 9.3K | #2,475,266 | View details | |
| icumed.com | 100% | 119.1K | #303,854 | View details | |
health.frederickcountymd.gov | health.frederickcountymd.gov | 92% | #1,208,001 | – | |
| oraquick.com | 91% | #1,540,355 | View details | ||
| questdiagnostics.com | 83% | 14.4M | #2,905 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for OraSure Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as OraSure Technologies (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orasure Technologies
Complete news archive for OraSure Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OraSure Technologies
OraSure Technologies was founded in 1987 and raised its 1st funding round 25 years after it was founded.
OraSure Technologies is headquartered in Bethlehem, United States.
Douglas A. Michels is the CEO of OraSure Technologies, as recorded in our data.
OraSure Technologies has 501 employees.
Annual revenue of OraSure Technologies is $115.02M as on Dec 31, 2025.
OraSure Technologies, Inc. is involved in the development, manufacture, and distribution of rapid diagnostic tests and sample collection solutions. The company operates within the healthcare sector, focusing on improving access, quality, and value of medical services. Products are distributed globally to clinical laboratories, hospitals, clinics, public health organizations, and direct to consumers. Subsidiaries like DNA Genotek and Sherlock Biosciences contribute to innovative solutions for detecting critical medical conditions such as HIV, HCV, and syphilis.
OraSure Technologies's top competitors include Quantalife, Senzo and Hememics Biotechnologies.
OraSure Technologies offers Rapid Diagnostic Tests and Sample Collection Devices.
Yes, OraSure Technologies is publicly traded on NASDAQ under the ticker symbol OSUR.
OraSure Technologies has made 6 acquisitions, including CoreBiome, DNA Genotek, and Diversigen.
OraSure Technologies has 3 investors. Key investors include Gates Foundation, HHS, and Public Health Emergency.
OraSure Technologies operates through Orasure Technologies, Inc..